Enorama Pharma ABOMXSTO: ERMA

ERMA: Strong US snus growth offset by NRT write-down; urgent capital needs remain

· Issued by Enorama Pharma AB

Net sales surged to 15.8 MSEK, driven by US snus sales, but losses deepened due to a 17 MSEK NRT write-down. Liquidity is low, with further capital raises needed to fund the ongoing US PMTA process and ensure going concern.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Enorama Pharma AB on 6ix

Earlier from Enorama Pharma

Later from Enorama Pharma

All Enorama Pharma news releases